Aesthetic Medical International Holdings Group Ltd - Annual Report Guide

I’m creating this guide to help you understand AIH’s performance. My goal is to explain their filings clearly so you can decide if this company fits your investment goals.

1. What does this company do?

AIH provides aesthetic medical services in China through nine hospitals and clinics. They offer three main services: surgical procedures (like rhinoplasty), non-surgical treatments (like Botox), and general healthcare (like dental care). They make money by charging patients fees for these services.

2. The "Structure" Risk

You do not actually own the clinics. Because Chinese law limits foreign ownership in this sector, AIH uses a "Variable Interest Entity" structure. You are betting on legal contracts, not physical assets.

• The "Chop" Risk: Local managers hold the official company seals, known as "chops." In China, these seals grant legal authority. If a manager goes rogue, they could move assets or sign contracts without permission. The parent company would have little power to stop them.
• Government Control: The Chinese government can change the rules at any time. If regulators decide these contracts violate foreign investment laws, they could cancel them. This would cut the parent company off from the clinics' profits, leaving shareholders with no legal claim to the business.

3. Financial Health & Operational Risks

• Revenue Dip: Revenue fell from RMB 755.7 million in 2024 to RMB 722.9 million in 2025. Fewer patients visited, and those who did spent less.
• Deepening Losses: The company lost RMB 54.1 million in 2025. This is more than double the RMB 25.1 million loss from 2024, caused by rising costs and weak demand.
• Cash Flow Warning: In 2025, the company spent more cash than it brought in from daily operations. They are burning through their savings, which limits their ability to grow or pay bills.
• Debt Crunch: They owe RMB 144.3 million to banks, with RMB 129.1 million due within a year. Because they are losing cash, they may need to issue more shares—reducing your ownership percentage—or restructure debt to avoid default.
• Family-Run Board: The founder’s family controls the company. Many board members are related, which limits independent oversight. This concentration of power means the family might prioritize their own interests over yours.

4. The "Red Tape" Minefield

• Advertising Crackdown: New rules from October 2025 restrict marketing. By banning "before-and-after" photos and livestream sales, regulators have cut off the company’s best ways to attract new customers.
• No Malpractice Insurance: The company carries no malpractice insurance. If a medical error or surgical complication occurs, the company must pay all legal costs and settlements itself. A single major incident could threaten the company’s survival.

5. The "Black Box" & Investor Rights

• No Dividends: They have never paid a dividend and have no plans to start. They are using existing capital to cover deficits.
• No R&D: The company spent nothing on research and development from 2023 to 2025. They are not innovating, which leaves them vulnerable to competitors who offer more modern procedures.

Final Thought for Investors: When looking at AIH, consider whether the potential for a rebound in the aesthetic market outweighs the significant risks of their corporate structure, the lack of malpractice insurance, and the current trend of deepening financial losses. Given the cash flow issues and the regulatory environment, this company currently faces substantial hurdles to profitability.